Prostate cancer presents challenges in detection, treatment, and management. Learn about genetic risks, treatment resistance, ...

The drug, known as NXP800, works by targeting the heat shock factor 1 (HSF1) pathway, a cellular protective mechanism that is hijacked to support the growth of cancer.

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone therapy enzalutamide.

In 2024, Feng received the “Mentorship Award” from ASTRO. In December, the American Society for Clinical Oncology (ASCO) ...

Hormone therapy does not appear to increase the risk of glioma among women in the United States, data suggest.

A breakthrough in prostate cancer treatment has seen a drug shrink tumours in advanced disease ...

Prostate cancer remains one of the most prevalent cancers among men worldwide. For patients with advanced or metastatic ...

In some instances, a man's prostate cancer biopsy can indicate perineural invasion. In an exclusive interview, an expert ...

A new study has found that many cases of high-risk nonmetastatic hormone-sensitive ... PET in accurately staging prostate cancer, which can significantly impact treatment decisions and outcomes ...

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year ...

PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research ...